Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. That said, here are three value stocks with little support and some other investments you should consider instead.
Mohawk Industries (MHK)
Forward P/E Ratio: 12.6x
Established in 1878, Mohawk Industries (NYSE: MHK) is a leading producer of floor-covering products for both residential and commercial applications.
Why Do We Think MHK Will Underperform?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Free cash flow margin is not anticipated to grow over the next year
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
At $122.84 per share, Mohawk Industries trades at 12.6x forward P/E. Read our free research report to see why you should think twice about including MHK in your portfolio.
CVS Health (CVS)
Forward P/E Ratio: 11.4x
With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE: CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary.
Why Are We Hesitant About CVS?
- Annual sales growth of 6.4% over the last two years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand
- Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 2.9% annually
- ROIC of 5.3% reflects management’s challenges in identifying attractive investment opportunities, and its shrinking returns suggest its past profit sources are losing steam
CVS Health’s stock price of $78.83 implies a valuation ratio of 11.4x forward P/E. To fully understand why you should be careful with CVS, check out our full research report (it’s free).
Navient (NAVI)
Forward P/E Ratio: 11.6x
Spun off from Sallie Mae in 2014 to handle the company's loan servicing and collection operations, Navient (NASDAQ: NAVI) provides education loan servicing and business processing solutions that help manage federal student loans, private education loans, and government services.
Why Should You Dump NAVI?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 18.7% annually over the last five years
- Earnings per share have dipped by 17.1% annually over the past five years, which is concerning because stock prices follow EPS over the long term
- Debt-to-equity ratio of 18.6× is concerningly high, indicating excessive leverage that could limit financial flexibility
Navient is trading at $12.51 per share, or 11.6x forward P/E. If you’re considering NAVI for your portfolio, see our FREE research report to learn more.
Stocks We Like More
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
